New hope for stem cell transplant complication: AC-003 trial launches
NCT ID NCT07070674
First seen Mar 17, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This early-stage trial tests a new drug called AC-003 in 24 adults who developed acute graft-versus-host disease (aGVHD) after a stem cell transplant and did not respond to standard steroids. The main goal is to check the drug's safety and how the body processes it, while also looking at whether it helps control the disease. Participants take AC-003 capsules and are monitored for side effects and response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hematology Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences)
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.